allogeneic CAR type III NKT-cell therapy (Akeso Therapeutics)

N/A

Report date: 2025/03/14 16:20:48

Base Information

Drug Nameallogeneic CAR type III NKT-cell therapy (Akeso Therapeutics)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionT lymphocytes stimulantsNatural killer T-lymphocyte stimulantsImmunostimulants

TargetsUpdating

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesN/A

China Registration ClassN/A

Develop Information

Active Companies +[1] N/A

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A